BioNotebook: Three collaborations, a buyout, four financings, two IPOs
This article was originally published in Scrip
Executive Summary
Advaxis and Incyte, two active collaborators in the immuno-oncology field, will test their drugs together in cervical cancer. The companies will co-fund and conduct a 20-patient Phase II clinical trial starting later this year to evaluate the Advaxis immunotherapy ADXS-HPV alone and in combination with Incyte's indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor epacadostat (INCB24360) in women with Stage 1 to 2a human papillomavirus (HPV)-associated cervical cancer.